Absci Corporation (ABSI)
- Previous Close
2.9600 - Open
2.9700 - Bid 2.8500 x 800
- Ask 2.9200 x 800
- Day's Range
2.8500 - 3.0650 - 52 Week Range
2.0100 - 6.3300 - Volume
2,887,334 - Avg. Volume
3,574,574 - Market Cap (intraday)
367.37M - Beta (5Y Monthly) 2.20
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9300 - Earnings Date Aug 12, 2025 - Aug 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.12
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, and Owkin for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
www.absci.comRecent News: ABSI
View MorePerformance Overview: ABSI
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABSI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABSI
View MoreValuation Measures
Market Cap
367.37M
Enterprise Value
242.30M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
69.69
Price/Book (mrq)
1.85
Enterprise Value/Revenue
50.32
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.52%
Return on Equity (ttm)
-48.97%
Revenue (ttm)
4.82M
Net Income Avi to Common (ttm)
-107.48M
Diluted EPS (ttm)
-0.9300
Balance Sheet and Cash Flow
Total Cash (mrq)
133.98M
Total Debt/Equity (mrq)
4.49%
Levered Free Cash Flow (ttm)
-35.49M